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To assess the relative merit of increased serum levels of vascular endothelial growth factor and basic ﬁbroblastic growth factor
in predicting the risk of disease progression of patients with early B-cell chronic lymphocytic leukaemia we analyzed 81 Binet
stage A patients whose sera were taken at the time of diagnosis and evaluated for the presence of vascular endothelial growth
factor and basic ﬁbroblast growth factor using an enzyme-linked immunosorbent assay. Serum levels of vascular endothelial
growth factor positively correlated with Rai sub-stages (P=0.03), peripheral blood lymphocytosis (P=0.03), bone marrow
histology (P=0.04) and b2-microglobulin (b2-m) (P=0.006). When dealing with basic ﬁbroblast growth factor only a correlation
with Rai sub-stages (P=0.02) could be found. Different cut-offs set on the basis of a stratiﬁcation in quartiles, failed to
demonstrate any correlation between serum levels of basic ﬁbroblast growth factor and disease progression. In contrast,
patients with increased serum levels of vascular endothelial growth factor (above median value, 203 pg ml
71) had a three times
increased risk of disease progression, although, in multivariate analysis only Rai sub-stages (P=0.0001) and lymphocyte doubling
time (P=0.002) retained their prognostic signiﬁcance. Low levels of vascular endothelial growth factor were indicative of good
clinical outcome in the subgroup of patients with either low (P=0.02) or high (P=0.03) b2-m concentration. Finally, the highest
prognostic power was obtained when serum vascular endothelial growth factor and b2-m were examined in combination.
Median of progression-free survival of patients who had both serum vascular endothelial growth factor and b2-m higher than
median value was only 13 months, in contrast median progression-free survival of patients with one marker increased (i.e.
above the 50th percentile) was 40 months. Patients with both markers below the median experienced the best clinical
outcome (median progression-free survival not reached at 40 months). In conclusion, serum levels of either vascular endothelial
growth factor or basic ﬁbroblast growth factor are high in patients with early chronic lymphocytic leukaemia, however, only
vascular endothelial growth factor predicts behaviour of disease and helps to reﬁne the prognosis of stage A patients.
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In patients with cancer, high serum concentrations of VEGF are
associated with several unfavourable clinical parameters such as
short tumour volume doubling time, progressive disease, extensive
disease and poor survival (Dirix et al, 1996, 1997; Salven et al,
1997a,b Kitamura et al, 1998; Tempfer et al, 1998; Ugurel et al,
2001). Similarly, high concentrations of b-FGF have been detected
in either urine or serum of cancer patients and associated with
tumour bulk in head and neck or with a short tumour volume
doubling time in colorectal cancer (O’Brien et al, 1995; Leunig et
al, 1998; Kumar et al, 1998). More recently, high pretreatment level
of b-FGF has been found an independent predictor of poor prog-
nosis in non-Hodgkin lymphomas (NHLs) (Salven et al, 1999b).
Furthermore, the simultaneous measurements of VEGF and b-
FGF provide prognostic information additional to international
prognostic index (IPI) (Salven et al, 2000).
Recent studies indicate that angiogenesis may also be involved in
the pathogenesis of B-cell chronic lymphocytic leukaemia (CLL)
(Aguayo et al, 2000; Kini et al, 2000). Elevated pretreatment levels
of b-FGF correlate with a more advanced clinical stage and with
resistance to chemotherapy (Menzel et al, 1996; Konig et al,
1997), while low cellular and high serum levels of VEGF are asso-
ciated with a poor clinical outcome (Molica et al, 1999; Aguayo et
al, 2000). Although these data lend support to the idea that angio-
genic cytokines may play a role in the leukaemogenic process of
CLL, the relative merit of VEGF and b-FGF in predicting the
outcome of disease has not been assessed thus far.
In this study we expanded on previous observation by evaluating
VEGF and b-FGF in the serum of patients with early CLL (i.e.,
Binet stage A) (Binet et al, 1981). In this subset of patients angio-
genic cytokines were investigated as indicator of disease-
progression (DP), an event which has an important impact on
overall survival of CLL patients.
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CLL patients
Eighty-one CLL Binet stage A (Binet et al, 1981) patients treated at
our institution form the basis of this study. Their median age was
66 years (range, 44–82 years) and the male to female ratio 49 to
32 years. Routine laboratory studies of these patients were
performed at diagnosis and consisted of complete blood count with
differential, platelet count, and blood chemistry including b-2
microglobulin (b-2m) and LDH, immunophenotyping to establish
the diagnosis of typical CLL (Cheson et al, 1996). Physical exami-
nation, chest X-ray, and abdominal ultrasound were performed in
all instances.
Patients were also staged according to the Rai (Rai et al, 1975)
staging system and distributed as follows: stage 0, 54 patients
(66.6%); stage I, seven patients (8.6%); stage II, 20 patients
(24.6%). BM biopsies were performed at the time of diagnosis in
63 (77.7%) out of 81 patients and the pattern of BM involvement
was evaluated according to the criteria suggested by Rozman et al
(1984). Lymphocyte doubling time (LDT), available in 73 patients
(90.1%) patients followed-up for a period 412 months was
assessed according to the method of Montserrat et al (1986).
Determination of serum levels of VEGF and b-FGF Peripheral
venous blood samples were collected in sterile tubes at the time of
CLL diagnosis, centrifugated at 2000 g for 10 min and stored at
7708C. VEGF and b-FGF concentrations were determinated by
using a quantitative ELISA technique (Human VEGF and human
b-FGF, Quantikine
TM and Quantikine
1; R&D Systems, Minneapo-
lis, MN, USA) as previously reported (Molica et al, 1999).
Concentrations were reported as pg ml
71. The sensitivity of test
was less than 5 pg ml
71 for VEGF and less than 3 pg ml
71 for
b-FGF. The coefﬁcient of variation (CV) of interassay determina-
tions reported by manufacturer vary from 6.2–8.8% and the
intra-assay variation from 2 to 9% for VEGF. As far as b-FGF is
concerned, the CV of interassay determinations reported vary from
7.4 and 9.1% while the intra-assay variation from 3 to 9.7%
Serum samples from 63 healthy blood donors (40 males and 23
females) without any evidence of diseases (i.e., liver dysfunction,
diabetes, etc.) whose age ranged between 40 and 65 years were
analyzed for VEGF presence. Given the consistent difference in
the serum levels of b-FGF between CLL patients and healthy
donors, for such a comparison only 20 normal controls were
considered sufﬁcient. The previously correlation between serum
VEGF levels and platelet count (Banks et al, 1998; Fuhrmann-
Benzakein et al, 2000) prompted us to measure VEGF concentra-
tion on either plasma or serum in 30 unselected CLL Binet stage
A patients. Different modalities of sample collection did not
prevent us from ﬁnding a close correlation between circulating
levels of VRGF and platelet count on either serum (r=0.524;
P50.0001) or plasma (r=0.449; P50.0001).
Other assays b-2 m and LDH serum levels were determinated as
previously described (Molica et al, 1999).
Clinical studies and disease-progression evaluation
Serum levels of either VEGF or b-FGF were correlated with main
clinical variables such as Rai clinical sub-stages, BM histology,
absolute PB lymphocytosis, LDT, LDH and b2-m. Furthermore,
VEGF and b-FGF were investigated as predictor of clinical
outcome. To this purpose we used as end-point disease-progression
(DP) deﬁned as the appearance of the upper stages according to
the Binet (Binet et al, 1981) classiﬁcation during the treatment-free
period. As previously reported, DP has an important impact on
overall survival of CLL patients in early disease stage (Molica,
1991). Therefore, DP can surrogate overall survival, thus shorten-
ing the duration of clinical studies in CLL.
Statistical methods
Pearson correlation, Spearman correlation and the corrected w
2 test
were applied to compare groups. Progression-free survival (PFS)
curves were plotted according to the method of Kaplan–Meier
and compared with the log-rank test. To evaluate the relative
signiﬁcance of some prognostic factors, the multiple regression
model of Cox was applied . The set variables analyzed were as
follows: stage according to Rai staging (0 vs I–II) , LDT (512
vs 412 months), absolute lymphocyte count (520 vs
420610
9/l), LDH (5425 vs 425 U l
71), b-2 m (52.89 vs
42.89 mg l
71), sVEGF (5203 vs 4203 ng ml
71). The cut-off
values of four continuous variables was determinated on the basis
of median value of entire patient population.
RESULTS
Serum VEGF and b-FGF concentrations in stage A B-cell
CLL patients
As shown in Figure 1, serum levels of VEGF and b-FGF were high-
er in stage A CLL patients in comparison to healthy controls
(P=0.028 and P50.0001, respectively).
The relationship between VEGF and b-FGF serum levels and
main clinico-hematological features of CLL is presented in Table
1. Serum levels of VEGF positively correlated with Rai substages
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Figure 1 Serum levels of VEGF and b-FGF. This box plot compares
median levels of VEGF (A) and b-FGF (B) in stage A B-cell CLL and healthy
controls.
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(P=0.04), b2-m (P=0.006). In contrast, only a correlation with
Rai clinical substages (P=0.02) could be found when dealing with
b-FGF.
Serum levels of VEGF and b-FGF and the risk of
disease-progression
The impact of VEGF and b-FGF on the clinical outcome of disease
was evaluated using as end-point DP. After a median follow-up time
of 15 months (range, 2–51 months), 26 out of 81 (32%) stage A
patients moved to a more advanced clinical stage (13 from stage A
to B, 13 from stage A to C). Different cut-offs set on the basis of a
stratiﬁcation in quartiles failed to demonstrate any correlation
between serum levels of b-FGF and DP (data not shown). In contrast,
when dealing with VEGF clear-cut differences could be appreciated at
a median value (i.e., 203 pg ml
71). Median time of PFS was 24
months for patients with VEGF serum levels above the median value,
whereas it was 51 months for patients with concentration of VEGF
below median value (P=0.002; hazard risk (HR), 0.321; 95% CI,
0.124–0.643) (Figure 2). The correlation between VEGF serum levels
and platelet count prompted us to evaluate whether platelet count
had any prognostic value in the current series. No association was
found between platelet count and the risk of DP (P=0.09), thus it
appears that circulating levels of VEGF are high in stage A CLL
patients with poor outcome and such a ﬁnding is an independent
prognostic factor irrespective of platelet count. In terms of relative
risk (RR), patients with higher levels of VEGF had a three times
increased risk of DP (RR, 3.27; 95% CI, 1.23–8.58) which was lower
than relative risks associated with Rai substages (RR, 7.39; 95% CI,
2.66–20.49), LDT (RR, 7.20; 95% CI, 2.72–18.92) and BM histology
(RR, 8.71; 95% CI, 2.29–32.7). As a matter of fact, in the multivariate
analysis only Rai substages (P=0.0001) and LDT (P=0.002) retained
their prognostic signiﬁcance (Table 2).
The effect of serum VEGF levels on DP was evaluated after
dividing patients into groups with high b2-m (poor prognostic
subgroup) and low b2-m (good prognostic subgroup) concentra-
tions. For such a stratiﬁcation we used as cut-off the median b2-
m value (i.e., 2.73 mg l
71). Serum levels of VEGF higher than
median value (i.e., 203 pg ml
71) identiﬁed patients with worse
outcome in the subgroup with either low (HR, 0.200; 95% CI,
0.057–0.826; P=0.02; Figure 3A) or high b2-m (HR, 0.377; 95%
CI, 0.114–0.947; P=0.03; Figure 3B) concentration.
Finally, given the partial independence of VEGF from b2-m the
combined effect of these markers on DP of stage A patients was
studied. Patients with both markers increased (above the median
values) had the worst clinical outcome (median of PFS, 13 months)
while those with both markers low the best one (median of PFS
not reached at 44 months); in between there was an intermediate-
risk group characterized for having only one marker increased
(median of PFS, 40 months; w
2 for trend=13.04, d.f.=1,
P=0.0003; Figure 4).
DISCUSSION
Results of the current study show that serum concentrations of
either VEGF or b-FGF are increased in the serum of stage A
CLL patients but only serum levels of VEGF reﬂect clinico-haema-
tological features of tumour mass such as advanced Rai clinical
substages, high PB lymphocytosis, increased b2-m and diffuse
BM histology.
Most circulating VEGF is found in platelets and leukocytes and
released from the blood cells during the coagulation process (Banks
et al, 1998). However, also after taking into account leukocyte and
platelet counts circulating levels of VEGF are higher in cancer
patients than in healthy persons (Salven et al, 1999a). The ﬁndings
of present study are in keeping with this because platelet count did
not have any impact on the risk of DP, whereas the serum VEGF
concentration was associated with an increased risk to progress to a
more advanced clinical stage. Those patients whose concentrations
of VEGF were higher than median value had a three times
increased relative risk (RR) of DP. This RR was lower than the
relative risks associated with other well-deﬁned prognostic variable
in CLL such as Rai substages and LDT as a consequence serum
levels of VEGF were not signiﬁcant in the multivariate analysis.
Nonetheless, VEGF serum levels may be useful to reﬁne prognosis
of patients with early CLL; higher levels of sVEGF were associated
with a shorter time of DP in Binet stage A patients with either low
or high b2-m levels.
The partial independence of sVEGF from b2-m prompted us to
use these markers as a combined parameter and such a combina-
tion clearly determinated three prognostic groups. So different
serological markers that contribute individually to prognosis of
CLL such as b2-m and VEGF, integrating different clinical and
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Table 1 Association between serum levels of VEGF and b-FGF and clin-
ico-haematological features
Rai PB BM
substages lymphocytes histology LDT LDH b2m
VEGF 0.034* 0.036* 0.046* 0.102* 0.101* 0.006*
b-FGF 0.021* 0.357* 0.089* 0.181* 0.09* 0.205*
*P-values.
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Figure 2 Progression-free survival (PFS) curves of stage A patients stra-
tiﬁed on the basis of median value of sVEGF (i.e., 203 pg ml
71).
Table 2 Risk of disease progression for stage A patients
RR
P-value
Variable Cut-off (95% CI) Univariate Multivariate
VEGF 203 pg ml
71 3.27 0.0026 NS
(1.23–8.58)
Rai substages 0 vs I–II 7.39 0.0001 0.0001
(2.66–20.49)
LDT 12 months 7.20 0.0001 0.002
(2.72–18.92)
b2m 2.37 mg l
71 2.89 0.053 NS
(1.04–8.0)
PB Lymph 20610
9 l
71 – 0.350 NS
BM histology Non-D vs Diffuse 8.71 0.0001 Non tested
(2.29–32.7)
LDH 425 u l
71 3.29 0.023 0.062
(1.19–9.12)
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to those of a single marker.
To identify patients at higher risk of DP a number of indepen-
dent prognostic factors such as LDT, soluble CD23, b2-m and
serum thymidine kinase have been proposed in patients with early
CLL (Molica, 2001). More recently, genotypic aberrations have
been reported as important independent predictors of DP and
survival and two independent studies indicate that IgH gene muta-
tion status has relevant prognostic implications (Hamblin et al,
1999; Damle et al, 1999; Dohner et al, 2000). As a surrogate of
IgH gene evaluation Damle et al (1999) have suggested to take into
account CD38 expression which stands as an excellent prognostic
marker in CLL (Ibrahim et al, 2001). However, it is not clear what
is the applicability of all these markers in the setting of clinical
practice. When dealing with serum markers such as VEGF, a major
problem is the lack of standardized methods for their measure-
ments. As a result, prognostic cut-off may vary thus avoiding the
general applicability of many serum markers in the day-by-day
practice. For these reasons, the evaluation of serum levels of VEGF
should not be considered standard practice in patients with CLL,
rather, as shown in the present paper, VEGF might improve the
assessment of individual patient prognosis in early CLL. Finally,
given the use of DP as a survival surrogate end-point and the rela-
tively short follow-up our data should be taken with caution.
Furthermore, longitudinal studies of VEGF determinations are
needed in order to understand whether the progression of early
CLL takes place in two phases, prevascular and vascular, respec-
tively.
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